Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at William Blair dropped their Q1 2025 earnings per share estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, April 1st. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($1.49) for the quarter, down from their prior forecast of ($1.46). William Blair has a "Outperform" rating on the stock. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.79) per share. William Blair also issued estimates for Axsome Therapeutics' Q2 2025 earnings at ($1.31) EPS, Q3 2025 earnings at ($0.96) EPS, Q4 2025 earnings at ($0.60) EPS, FY2025 earnings at ($4.36) EPS, Q1 2026 earnings at ($0.44) EPS, Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at $0.47 EPS, Q4 2026 earnings at $1.13 EPS, FY2026 earnings at $1.10 EPS, FY2027 earnings at $12.30 EPS, FY2028 earnings at $25.02 EPS and FY2029 earnings at $38.11 EPS.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to analyst estimates of $117.83 million. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%.
AXSM has been the topic of several other research reports. Truist Financial lifted their price objective on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a report on Wednesday, February 19th. HC Wainwright reissued a "buy" rating and issued a $200.00 price target on shares of Axsome Therapeutics in a report on Thursday. Needham & Company LLC reissued a "buy" rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research note on Tuesday, April 1st. Mizuho raised their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research note on Thursday, March 27th. Finally, Leerink Partners upped their price objective on Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research note on Monday, February 10th. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $169.80.
Check Out Our Latest Analysis on AXSM
Axsome Therapeutics Stock Performance
AXSM stock traded down $0.36 during trading on Friday, reaching $98.50. 1,196,386 shares of the stock were exchanged, compared to its average volume of 666,956. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13. The company has a current ratio of 2.11, a quick ratio of 2.04 and a debt-to-equity ratio of 3.22. The company has a market capitalization of $4.80 billion, a P/E ratio of -16.44 and a beta of 0.88. The stock has a 50 day simple moving average of $120.62 and a 200-day simple moving average of $101.82.
Hedge Funds Weigh In On Axsome Therapeutics
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Raiffeisen Bank International AG acquired a new position in shares of Axsome Therapeutics in the 4th quarter valued at $51,000. Assetmark Inc. acquired a new position in Axsome Therapeutics in the fourth quarter valued at about $52,000. R Squared Ltd bought a new position in Axsome Therapeutics during the fourth quarter worth about $64,000. Aquatic Capital Management LLC acquired a new position in shares of Axsome Therapeutics during the 4th quarter worth about $76,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Axsome Therapeutics in the 4th quarter valued at about $86,000. 81.49% of the stock is owned by institutional investors.
Insider Transactions at Axsome Therapeutics
In related news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the transaction, the chief financial officer now owns 42,187 shares in the company, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 22.40% of the stock is owned by company insiders.
Axsome Therapeutics Company Profile
(
Get Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Further Reading
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
